Breakfast or not? new study tests Food's impact on brain drug
NCT ID NCT07292233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing how eating food changes the way the body absorbs a new experimental drug called LY03020. The drug is being developed for schizophrenia and psychosis related to Alzheimer's disease. Sixteen healthy volunteers will take the drug once with food and once without, so researchers can compare the levels in their blood and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY03020 (LPM787000048 maleate extended-release tablets)
What this could lead to
If successful, this study could help determine the best way to take LY03020 with or without food, guiding future trials for treating schizophrenia and Alzheimer's disease psychosis.
What could go wrong
This is a very early phase 1 trial in only 16 healthy people, not patients. It only measures how food affects drug levels, not whether the drug works for the intended conditions. The drug may still fail in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing AnDing Hospital Capital Medical University
Beijing, China